Noro Polymerase and Protease Inhibitors

Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
Norovirus Gastroenteritis CDI-988 Oral Protease Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started

We continue to identify and develop non-nucleoside polymerase inhibitors using our proprietary structure-based drug design technology platform. In 2020, we entered into a License Agreement with the Kansas State University Research Foundation to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat norovirus and coronavirus infections. Preclinical activities for our Norovirus program are currently under way.